COMMUNIQUÉS West-GlobeNewswire

Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019
22/01/2019
The proposition on a new board of directors in Oasmia presented by Arwidsro Investment AB and Per Arwidsson (jointly “Arwidsro”) only a short period before the planned general meeting does not comply with Nasdaq [...]
Immunicum AB (publ) Announces Upcoming Investor Events in January
22/01/2019
Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management [...]
ACACIA PHARMA ANNOUNCES SUPPORTIVE CARDIAC SAFETY DATA FOR BARHEMSYS™
22/01/2019
Cambridge, UK and Indianapolis, US – 22 January 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces results from its latest study of BARHEMSYS™ (intravenous amisulpride), its anti- [...]
Bone Therapeutics announces 2019 business outlook and reports year-end 2018 cash position
22/01/2019
Regulated information Phase IIA results with ALLOB in patients undergoing a spinal fusion procedure expected mid-2019 CTA submission planned in H2 2019 to start delayed-union fractures study with ALLOB Phase III study [...]
Bone Therapeutics annonce ses perspectives d’affaires pour 2019 et dresse son bilan de trésorerie
22/01/2019
Information réglementée Résultats de la phase IIA d’ALLOB pour les patients suivant une procédure de fusion vertébrale attendus pour la mi-2019 Demande d’autorisation d’essai clinique (CTA) pour l’étude d’ALLOB dans les [...]
Dr. Johan Luthman appointed EVP and Head of Research & Development in Lundbeck
22/01/2019
Valby, Denmark, 22 January 2019 - H. Lundbeck A/S (Lundbeck) today announced that Dr. Johan Luthman has been appointed Executive Vice President and Head of Research & Development in Lundbeck. Johan will assume his [...]
MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases
22/01/2019
LA JOLLA, Calif., Jan. 21, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), [...]
Federal Judge Recognizes Free Speech for Cannabis Producer
21/01/2019
First-of-its-kind Federal Court ruling affirms medical cannabis speech cannot be restrained ALBUQUERQUE, N.M., Jan. 21, 2019 (GLOBE NEWSWIRE) -- For the first time in history, a Federal Court order has recognized the [...]
GENFIT: ANNOUNCES ITS FINANCIAL CALENDAR FOR 2019
21/01/2019
GENFIT: ANNOUNCES ITS FINANCIAL CALENDAR FOR 2019 Lille (France); Cambridge (Massachusetts, United States) - January 21, 2019 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery [...]
GENFIT : ANNONCE SON CALENDRIER FINANCIER POUR 2019
21/01/2019
GENFIT : ANNONCE SON CALENDRIER FINANCIER POUR 2019 Lille (France) ; Cambridge (Massachusetts, États-Unis) - 21 janvier 2019 - GENFIT (Euronext : GNFT - ISIN : FR0004163111), société biopharmaceutique de phase avancée [...]
Ossur Hf : Transactions in relation to share buyback program
21/01/2019
Announcement no. 04/2019 21 January 2019 Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share [...]
Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)
21/01/2019
CAMBRIDGE, Mass., Jan. 21, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data [...]
SciCann Therapeutics launch liver disease research program in Tel Aviv University
21/01/2019
TORONTO and TEL AVIV, Israel, Jan. 21, 2019 (GLOBE NEWSWIRE) -- SciCann Therapeutics is pleased to announce that it has launched a novel sponsored research program in Tel Aviv University, focused on the field of liver [...]
Allocation of Share Options
21/01/2019
NASDAQ Copenhagen Report on transactions of executives and related parties in Coloplast shares and related securities. According to the Market Abuse Regulation art. 19 Coloplast is obliged to report on the transactions [...]
Physeon Positive Clinical Trial Results for its Veinplicity® Device Published in The Journal of Vascular Access
21/01/2019
Results Confirmed that Veinplicity Dilatory Effect is 38% Greater than Commonly Used Heat Packs SCHAFFHAUSEN, Switzerland, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading [...]
Sandoz Canada reçoit l’approbation de Santé Canada pour l’utilisation d’Erelzi® (étanercept) dans le traitement de l’arthrite psoriasique chez les patients adultes
21/01/2019
Erelzi est le seul biosimilaire d’étanercept indiqué pour réduire les signes et les symptômes de l’arthrite psoriasique chez les patients adultes. Jusqu’à 90 000 Canadiens et Canadiennes souffrent ou pourraient souffrir [...]
Novo Nordisk A/S - Share repurchase programme
21/01/2019
Bagsværd, Denmark, 21 January 2019 - On 5 November 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Solo Growth Announces Update to Corporate Presentation
21/01/2019
CALGARY, Alberta, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Solo Growth Corp.™ (the “ Company ” or “ Solo Growth ”) (TSXV: SOLO) is pleased to announce that we have updated our corporate presentation, which is now posted on our [...]
Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound In Second Pre-Clinical Study For Non-Alcoholic Fatty Liver Disease
21/01/2019
Compound Showed Marked Improvement Over Cenicriviroc VANCOUVER, British Columbia, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: [...]

Pages